Consultants Present on Malignancies, Cell Disorders, and More at 66th ASH Annual Meeting and Exposition
December 4, 2024
Analysis Group consultants will give two podium presentations and exhibit 16 research posters at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference will take place December 7–10, 2024, in San Diego, California.
Analysis Group’s podium presentations will include:
Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients with Pulmonary Embolism and Right Ventricular Dysfunction
December 8, 2024, 4:30 p.m., Room 6CF at the San Diego Convention Center
Coauthors include: Principal François Laliberté, Vice President Guillaume Germain, Manager Sean MacKnight, Senior Research Professional Julien Boudreau, Senior Analyst Manasvi Sundar, and researchers from Brigham and Women’s Hospital, Johnson & Johnson, Mass General Brigham Research Information Science & Computing, and Janssen Scientific Affairs (sponsor).
Real-World Effectiveness of Immunoglobulin Replacement Therapy on Hypogammaglobulinemia and Infectious Complications in Patients with Multiple Myeloma
December 8, 2024, 5:30 p.m., San Diego Ballroom AB at Marriott Marquis San Diego Marina
Coauthors include: Managing Principal Mei Sheng Duh, Vice President Lynn Huynh, Associate Raj Desai, and researchers from the Dana-Farber Cancer Institute, Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego, Mass General Brigham Research Information Science & Computing, Harvard Medical School, Massachusetts General Hospital, and Takeda Pharmaceuticals USA (sponsor).
The firm’s posters are expected to be presented in Halls G–H at the San Diego Convention Center, featuring research on:
Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA)
December 7, 2024, 5:30–7:30 p.m.
Coauthors include: Vice President Dominic Pilon, Associate Yan Meng, Research Professional Yuxi Wang, and researchers from the Mayo Clinic and BeiGene (sponsor).
Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs BTKi Therapies in 1L CLL: An International Real-World Study
December 9, 2024, 6:00–8:00 p.m.
Coauthors include: Managing Principal Annie Guérin, Vice President Irina Pivneva, Senior Research Professional Talissa Watson, and researchers from Columbia University; Dana-Farber Cancer Institute; Fred Hutch Cancer Center; Churchill Hospital; Atrium Health Levine Cancer Institute; Memorial Sloan Kettering Cancer Center; University of California, Irvine; Novant Health Cancer Institute; Cleveland Clinic Taussig Cancer Institute; John Theurer Cancer Center; Rutgers Cancer Institute of New Jersey; Hôpital Maisonneuve-Rosemont; University of Rochester; Nottingham University Hospitals NHS Trust; University of North Carolina at Chapel Hill; Tufts Medical Center; University of Massachusetts; Dartmouth-Hitchcock Medical Center; Stanford Cancer Institute; University of Pennsylvania; Lowell General Hospital; and AbbVie (sponsor).
Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States
December 7, 2024, 5:30–7:30 p.m.
Coauthors include: Managing Principal Hongbo Yang, Manager Wei Song, and researchers from The University of Texas MD Anderson Cancer Center, Genesis Research Group, Georgia Cancer Center at Augusta University, and Novartis Pharmaceuticals (sponsor).
Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) – A Chart Review Study in the United States
December 8, 2024, 6:00–8:00 p.m.
Coauthors include: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, Manager Carmine Rossi, Senior Research Professional Remi Bellefleur, and researchers from the Medical College of Wisconsin and Novartis Pharmaceuticals (sponsor).
Patient Medication Preferences in Follicular Lymphoma (FL) in the United States (USA): A Discrete-Choice Experiment (DCE)
December 8, 2024, 6:00–8:00 p.m.
Coauthors include: Manager Todor Totev, Associate Yan Meng, Senior Analyst Zhuo Chen, and researchers from Moffitt Cancer Center and BeiGene (sponsor).
A Retrospective Claims Analysis of Real-World Treatment Patterns and Economic Burden Among Patients with Marginal Zone Lymphoma in the US
December 9, 2024, 6:00–8:00 p.m.
Coauthors include: Managing Principal James Signorovitch, Vice President Yan Song, Manager Ambika Satija, Senior Data Scientist Ben Meade, and researchers from Merck Sharp & Dohme and Merck & Co. (sponsor).
Reducing Time Toxicity for Anti-B-Cell Maturation Antigen (BCMA) Bispecific Treatment: Evidence from Pivotal Single-Arm Trial Data on Teclistamab, Elranatamab, and Linvoseltamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
December 7, 2024, 5:30–7:30 p.m.
Coauthors include: Vice President Jenny Zhou, Associate Michael Xu, Senior Analyst Jack Eales, and researchers from the Mayo Clinic and Regeneron Pharmaceuticals (sponsor).
Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study’s Interim Results
December 8, 2024, 6:00–8:00 p.m.
Coauthors include: Managing Principal Mei Sheng Duh, Vice President Priyanka Bobbili, Manager Aolin Wang, Senior Analysts Manasi Mohan and Jingyi Chen, and researchers from the Mayo Clinic and Pfizer (sponsor).
Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study
December 8, 2024, 6:00–8:00 p.m.
Coauthors include: Vice President Marie-Hélène Lafeuille, Associate Alvi Rahman, Research Professional Claire Eynde, and researchers from Memorial Sloan Kettering Cancer Center, Florida Cancer Specialists & Research Institute, Allegheny Health Network Cancer Institute, UCLA Health, NYU Langone Health, Cedars-Sinai Medical Center, RJM Group, Oregon Health and Science University Knight Cancer Institute, Ascension Providence Hospital, Huntsman Cancer Institute, and Johnson & Johnson (sponsor).
Patient Characteristics, Treatment Patterns and Early Outcomes of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study
December 9, 2024, 6:00–8:00 p.m.
Coauthors include: Vice President Marie-Hélène Lafeuille, Manager Jessica Maitland, Associate Alvi Rahman, Senior Research Professionals Anabelle Tardif-Samson and Bronwyn Moore, and researchers from Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, and Johnson & Johnson (sponsor).
Overall Survival and Duration of Treatment in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib Versus Midostaurin or Best Available Therapy in a Real-World Setting
December 7, 2024, 5:30–7:30 p.m.
Coauthors include: Managing Principal Mei Sheng Duh, Vice President Priyanka Bobbili, Manager Aolin Wang, Senior Analyst Manasi Mohan, Analyst Teshawna Badu, and researchers from University Hospital Mannheim, Stanford Cancer Institute/Stanford University School of Medicine, Institute of Mastocytosis Studies of Castilla La Mancha, Guy’s and St Thomas’ NHS Foundation Trust, Dana-Farber Cancer Institute, the Medical University of Vienna, and Blueprint Medicines (sponsor).
Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States
December 8, 2024, 6:00–8:00 p.m.
Coauthors include: Managing Principal James Signorovitch, Vice President Gautam Sajeev, Manager Mirko Fillbrunn, Senior Analyst Adina Zhang, and researchers from Moffitt Cancer Center, IRCCS University Hospital of Bologna Policlinico di Sant’Orsola, Cleveland Clinic Taussig Cancer Institute, and GSK (sponsor).
Real-World Treatment Patterns, Healthcare Resource Use, and Costs Among Patients with Waldenström Macroglobulinemia: A Retrospective Analysis of US Claims Data
December 8, 2024, 6:00–8:00 p.m.
Coauthors include: Managing Principal James Signorovitch, Vice President Yan Song, Manager Ambika Satija, Senior Data Scientist Ben Meade, and researchers from Merck Sharp & Dohme and Merck & Co. (sponsor).
Real-World Effectiveness of Ravulizumab Among Adults with Atypical Hemolytic Uremic Syndrome (aHUS) Who Switched to Ravulizumab within 3 Months of Eculizumab Treatment: A Physician Panel-Based Chart Review Study (aHUS IMPACT)
December 8, 2024, 6:00–8:00 p.m.
Coauthors include: Managing Principal Mei Sheng Duh, Vice President Lynn Huynh, Associates Rui Song and Jordan Burdeau, and researchers from Johns Hopkins Hospital; University of California, Irvine; and Alexion, AstraZeneca Rare Disease (sponsor).
Real-World Treatment Patterns and Outcomes in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Interim Analysis Results
December 8, 2024, 6:00–8:00 p.m.
Coauthors include: Managing Principal Elyse Swallow, Vice President Debbie Goldschmidt, Associate Ali Greatsinger, Analyst Loren Ormenaj, and researchers from Miami Cancer Institute, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Johns Hopkins Hospital, and Sobi (sponsor).
Real-World Drug Adherence, Persistence, and Healthcare Resource Utilization in Patients with Paroxysmal Nocturnal Hemoglobinuria in the USA: The Advantage Study
December 9, 2024, 6:00–8:00 p.m.
Coauthors include: Managing Principal Maral DerSarkissian, Vice President Rose Chang, Associate Brendan Rabideau, and researchers from Roswell Park Comprehensive Cancer Center; Mayo Clinic; and Alexion, AstraZeneca Rare Disease (sponsor).
Read more about ASH’s Annual Meeting and Exposition